PorA Pharmaceuticals, LLC

PorA Pharmaceuticals is developing breakthrough pharmaceuticals to meet the antibiotic challenge. The lead compound is amixicile, a systemic antimicrobial that targets anaerobic organisms through inhibition of pyruvate: ferredoxin oxidoreductase (PFOR). The focus of the company is approval of amixicile to treat Clostridium difficile (c. diff) infection (CDI). CDI has emerged as the most common health-care-associated infection in the USA.